个性化运动处方对达芬奇机器人术后胰腺癌患者肌肉量、身体功能和生活质量的影响:随机对照试验方案
本研究为随机对照试验方案,计划纳入168例达芬奇机器人术后胰腺癌患者,按1:2随机分为干预组和对照组,干预组接受16周个性化运动处方,对照组不接受特定运动处方或干预。主要结局为第16周骨骼肌指数和密度变化、6分钟步行试验及标准化量表生活质量评分,次要结局包括FACT-F、HADS和PSQI。
要点
- 计划纳入168例达芬奇机器人术后胰腺癌患者,按1:2随机分为干预组和对照组。
- 干预组接受16周个性化运动处方,对照组不接受特定运动处方或干预。
- 主要结局为第16周肌肉量(骨骼肌指数和密度)、6分钟步行试验及生活质量量表评分。
核心结论
- 该试验旨在为个性化运动处方改善胰腺癌术后患者肌肉量、身体功能和生活质量的疗效提供新的临床见解。
研究设计与样本
- 随机对照试验方案,计划纳入168例符合条件的胰腺癌术后患者,按1:2比例随机分配至干预组或对照组。
- 干预组接受为期16周的个性化运动处方,对照组不接受任何特定运动处方或干预。
主要发现
- 主要结局包括从基线至第16周肌肉量变化(骨骼肌指数和密度)、6分钟步行试验评估的身体功能及标准化量表评分评估的生活质量。
- 次要结局包括癌症治疗功能评估疲劳量表(FACT-F)、医院焦虑抑郁量表(HADS)和匹兹堡睡眠质量指数(PSQI)。
- 除肌肉量外的结局指标分别在第0周、第4周和第12周进行测量。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pancreatic cancer is characterized by a 5-year survival rate of less than 12%, primarily because of challenges in early diagnosis, which has resulted in a generally poor prognosis for patients. With ongoing advancements in diagnostic and surgical technologies, there is an increasing focus on enhancing the postoperative quality of life for individuals with pancreatic cancer. Although existing research suggests that exercise interventions are safe for this patient population, definitive evidence regarding their efficacy remains insufficient. Consequently, this study aims to conduct a randomized controlled trial to assess the safety and efficacy of exercise interventions in enhancing muscle mass, physical function, and quality of life among patients who have undergone surgery for pancreatic cancer. METHODS: A total of 168 eligible postoperative pancreatic cancer patients will be enrolled and randomly allocated in a 1:2 ratio to either the intervention group or the control group. Participants in the intervention group will receive a personalized exercise prescription for a duration of 16 weeks, whereas participants in the control group will not receive any specific exercise prescription or intervention. The primary outcomes of this study include Changes in muscle mass, specifically the skeletal muscle index and density, from baseline to week 16, as well as assessments of physical function using the 6-Minute Walk Test (6MWT) and evaluations of quality of life through standardized scale scores. Secondary outcomes comprise assessments using the Functional Assessment of Cancer Therapy Fatigue Scale (FACT-F), the Hospital Anxiety and Depression Scale (HADS), and the Pittsburgh Sleep Quality Index (PSQI). Measurements of outcome indicators other than muscle mass will be conducted at weeks 0, 4, and 12, respectively. DISCUSSION: The impact of the personalized exercise prescription intervention will be evaluated through alterations in primary and secondary outcome indicators at both the 4-week intervention mark and the 12-week follow-up period. This trial aims to offer novel clinical insights into the efficacy of personalized exercise prescriptions in enhancing muscle mass, physical function, and quality of life among postoperative pancreatic cancer patients. TRIAL REGISTRATION: Clinical Trial Registry-China ChiCTR2500098709. Registered on 12 March 2025.
引用
- Liu M, Ren T. Impact of personlized exercise prescription on muscle mass, physical function, and quality of life in postoperative pancreatic cancer patients undergoing da Vinci robotic surgery: a randomized controlled trial protocol. Trials. 2025. PMID: 41102825. doi:10.1186/s13063-025-09078-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。